



CORRIGENDUM to ‘Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN’

Cephalalgia

2021, Vol. 41(9) 1035

© International Headache Society 2021

Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/03331024211015848

journals.sagepub.com/home/cep



John H Krege, Paul B Rizzoli, Emily Liffick, et al. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN. *Cephalalgia* 2019; 39(8): 957–966. DOI: 10.1177/0333102419855080.

On page 960, top of the right-hand column, the sentence incorrectly stated ‘The only **SAE** with incidence >1% in any group was dizziness in the lasmiditan 200 mg group.’

This sentence should correctly state ‘The only **severe TEAE** with incidence >1% in any group was dizziness in the lasmiditan 200 mg group’.